Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwMyeloma 2016 | Tolerability of monoclonal antibodies in multiple myeloma

Thomas Martin • 22 Apr 2016
iwMyeloma 2016
Multiple Myeloma Antibodies

Thomas Martin, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the tolerability of monoclonal antibodies. According to Prof Martin, monoclonal antibodies are well tolerated, however, at the first infusion there can be infusion-related reactions.
Recorded at the Myeloma 2016 meeting held in Boston, MA.

More from Thomas Martin

Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more 14:14
Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more
Adriana Rossi et al. • 12 Apr 2025
Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies
Ajai Chari et al. • 4 Nov 2024
Sequencing immunotherapies in multiple myeloma 1:57
Sequencing immunotherapies in multiple myeloma
Thomas Martin • 24 May 2024
Ide-cel versus cilta-cel in multiple myeloma: a collaborative decision between patient and doctor 1:33
Ide-cel versus cilta-cel in multiple myeloma: a collaborative decision between patient and doctor
Thomas Martin • 24 May 2024

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals